webinar register page

Recombinant Therapeutic pAbs Are Now Possible
Polyclonal antibodies are popular research reagents for their high sensitivity and robust cross-platform performance. But few companies consider them viable for therapeutic applications as they are almost impossible to characterize. Additionally, they suffer from a lack of reproducibility and limited supply.

Monoclonal antibodies (mAbs) can be reliably characterized and produced for therapeutic applications, but are more costly to discover and develop.

Rapid Novor’s REpAb technology can overcome these limitations by capturing the sequences of the most abundant IgG in a pAb and enabling indefinite antibody production. Here we report the first successful conversion of a goat polyclonal antibody into a cocktail of recombinant mAbs using only the pAb protein sample.

00:47:00

* Required information
Loading